IGFBP3 and ductal breast carcinoma in situ: Moreover, both the histological location of IGFBP-3 and variations in its immunoreactivity have been compared in this series of invasive ductal breast cancers with concomitant evaluation of IGFBP-3 expression in synchronous ductal carcinoma in situ (DCIS) within the same tumour specimens.